HIV

GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors
Fierce Pharma
GSK
ViiV Healthcare
Dovato
DTC ads
HIV
Flag link:
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Marketwatch
JNJ
Janssen
tuberculosis
HIV
philanthropy
Flag link:
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Endpoints
Gilead Sciences
Descovy
HIV
PrEP
FDA
Truvada
generics
Flag link:
Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech
Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech
Endpoints
GSK
ViiV
Tivicay
HIV
HemoShear
Flag link:
HIV vaccine shows signs of cross-subtype protection
HIV vaccine shows signs of cross-subtype protection
Fierce Biotech
vaccines
HIV
ALVAC‐HIV
Sanofi Pasteur
GSK
JNJ
South Africa
clinical trials
Flag link:
HIV-focused Gilead launches fund, pledges $2M to help transgender people
HIV-focused Gilead launches fund, pledges $2M to help transgender people
Fierce Pharma
Gilead Sciences
HIV
transgender
philanthropy
Flag link:
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
NPR
HIV
CRISPR
gene editing
Flag link:
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
GSK's ViiV reports positive data for long-acting two-drug HIV therapy
Biopharma Dive
ViiV Healthcare
GSK
HIV
cabotegravir
rilpivirine
Flag link:
Antiretroviral Therapy's Positive Impact On Global Public Health Faces Challenges Moving Forward
Antiretroviral Therapy's Positive Impact On Global Public Health Faces Challenges Moving Forward
Forbes
HIV
Public Health
antiretrovirals
Flag link:
Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Roche Expands Global Access to Viral Assays to Aid Eradication Efforts
Medical Devices and Diagnostics Industry
Roche
viral assays
HIV
HPV
diagnostics
Global Access Program
Flag link:
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
Endpoints
FDA
Gilead Sciences
HIV
Descovy
PrEP
Flag link:
Regulators, Gilead at odds over HIV drug's use in women
Regulators, Gilead at odds over HIV drug's use in women
Biopharma Dive
Gilead Sciences
HIV
Descovy
Flag link:
ViiV’s first-in-class HIV drug on course for filings this year
ViiV’s first-in-class HIV drug on course for filings this year
Pharmaforum
ViiV Healthcare
HIV
fostemsavir
FDA
Flag link:
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Endpoints
Gilead Sciences
Durect
HIV
hepatitis B
extended release
Flag link:
J&J gears up for clinical test of HIV vaccine efficacy
J&J gears up for clinical test of HIV vaccine efficacy
Fierce Biotech
JNJ
clinical trials
HIV
vaccines
Flag link:
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Yahoo/Zacks.com
GSK
HIV
FDA
Merck
Keytruda
Sanofi
isatuximab
Roche
JNJ
Flag link:
Scripps Research Snags $129 Million for HIV Vaccine Investigation
Scripps Research Snags $129 Million for HIV Vaccine Investigation
BioSpace
Scripps Research Institute
HIV
vaccines
Flag link:
ViiV's HIV Drug Hits Endpoints in Late-Stage Comparison Trial
ViiV's HIV Drug Hits Endpoints in Late-Stage Comparison Trial
BioSpace
GSK
ViiV Healthcare
Dovato
HIV
Flag link:
Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies
Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies
BioSpace
Gilead Sciences
Lyndra Therapeutics
HIV
Flag link:
ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment
ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment
Pharmaceutical Business Review
ViiV Healthcare
HIV
cabotegravir
rilpivirine
Flag link:

Pages